Protalix BioTherapeutics, Inc. (PLX)
 NYSEAMERICAN: PLX · Real-Time Price · USD
 2.315
 +0.055 (2.43%)
  Oct 31, 2025, 1:39 PM EDT - Market open
Protalix BioTherapeutics Revenue
Protalix BioTherapeutics had revenue of $15.66M in the quarter ending June 30, 2025, with 16.21% growth. This brings the company's revenue in the last twelve months to $61.95M, up 62.79% year-over-year. In the year 2024, Protalix BioTherapeutics had annual revenue of $53.40M, down -18.47%.
Revenue (ttm) 
 $61.95M
Revenue Growth 
 +62.79%
P/S Ratio 
 2.73
Revenue / Employee 
 $290,836
Employees 
 213
Market Cap 
184.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 53.40M | -12.10M | -18.47% | 
| Dec 31, 2023 | 65.49M | 17.86M | 37.48% | 
| Dec 31, 2022 | 47.64M | 9.29M | 24.22% | 
| Dec 31, 2021 | 38.35M | -24.55M | -39.03% | 
| Dec 31, 2020 | 62.90M | 8.21M | 15.00% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Eli Lilly and Company | 53.26B | 
| Novo Nordisk | 49.11B | 
PLX News
- 14 days ago - Why Is Protalix BioTherapeutics Stock Falling On Friday? - Benzinga
- 14 days ago - Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU - GlobeNewsWire
- 7 weeks ago - Protalix BioTherapeutics to Present at Investor Summit Virtual - Accesswire
- 2 months ago - Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 2 months ago - Protalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio Ramp - Seeking Alpha
- 2 months ago - Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results - PRNewsWire
- 3 months ago - Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025 - PRNewsWire